Whole-blood transcriptome profiling reveals signatures of metformin and its therapeutic response

Metformin, a biguanide agent, is the first-line treatment for type 2 diabetes mellitus due to its glucose-lowering effect. Despite its wide application in the treatment of multiple health conditions, the glycemic response to metformin is highly variable, emphasizing the need for reliable biomarkers....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2020-08, Vol.15 (8), p.e0237400-e0237400
Hauptverfasser:	Ustinova, Monta, Ansone, Laura, Silamikelis, Ivars, Rovite, Vita, Elbere, Ilze, Silamikele, Laila, Kalnina, Ineta, Fridmanis, Davids, Sokolovska, Jelizaveta, Konrade, Ilze, Pirags, Valdis, Klovins, Janis
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Antidiabetics Biological markers Biology and Life Sciences Biomarkers Biomedical research Blood Breast cancer CCR2 protein CD14 antigen CD163 antigen Cell division Cholesterol Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Drug therapy Electron transport chain Endocrinology Ethics Gastrointestinal cancer Gene expression Genes Genomes Glucose Homeostasis Human rights Hyperglycemia Immune response Insulin resistance IRS-2 gene Kinases Medicine Medicine and Health Sciences Metformin Mitochondria Monocyte chemoattractant protein 1 Patients Physiological aspects Research and analysis methods Ribonucleic acid RNA RNA sequencing Stem cells Studies Testing Transcriptomics Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!